CS acquires AxeroVision’s dry eye disease pipeline
CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes. Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular… Read More